CAJ | 학술논문

目的：观察依达拉奉联合低分子肝素治疗急性进展型脑梗死的疗效。方法选取我院2014年6月～2015年1月收治的急性进展型脑梗死患者80例，根据不同治疗方案分为对照组45例与研究组35例，对照组给予常规治疗，研究组给予依达拉奉联合低分子肝素治疗，对比两组治疗前后神经功能缺损程度（NIHSS）评分变化情况与疗效。结果治疗后研究组NIHSS评分低于对照组，差异有统计学意义（P＜0.05）；研究组总有效率为94.29%高于对照组的71.11%，差异有统计学意义（P＜0.05）。结论依达拉奉联合低分子肝素治疗急性进展型脑梗死疗效显著，值得临床推广。
목적：관찰의체랍봉연합저분자간소치료급성진전형뇌경사적료효。방법선취아원2014년6월～2015년1월수치적급성진전형뇌경사환자80례，근거불동치료방안분위대조조45례여연구조35례，대조조급여상규치료，연구조급여의체랍봉연합저분자간소치료，대비량조치료전후신경공능결손정도（NIHSS）평분변화정황여료효。결과치료후연구조NIHSS평분저우대조조，차이유통계학의의（P＜0.05）；연구조총유효솔위94.29%고우대조조적71.11%，차이유통계학의의（P＜0.05）。결론의체랍봉연합저분자간소치료급성진전형뇌경사료효현저，치득림상추엄。
Objective To observe the clinical effect of 35 cases of edaravone combined with low molecular weight heparin in the treatment of acute progressive cerebral infarction.Methods A retrospective analysis of our hospital in June 2014 and January 2015 treated 80 cases of acute progressive cerebral infarction patients clinical data, according to the different treatment options is divided into two groups, the control group (45 cases) received routine treatment and the study group (35 cases) treated with Yiyidala Bong combined with low molecular weight heparin in the treatment of, comparing the two groups before and after treatment of neurological deficit (NIHSS) score changes and clinical curative effect.Results After treatment, the NIHSS score of the study group was lower than that of the control group (P<0.05); the total effective rate of the study group was 71.11% higher than that of the control group (P<0.05).Conclusion Edaravone combined with low molecular weight heparin in treatment of acute progressive cerebral infarction significantly.